The Bard Urological Division of C.R. Bard Inc. has filed to begintesting a biomaterial to treat urinary incontinence. The injectablegel made by Biomatrix Inc. (NASDAQ:BIOX) is a chemically cross-linked form of a natural carbohydrate, hyaluronan.
The submission for an investigational device exemption requestsauthorization to start clinical trials of Hylagel-Muscle, which wouldbe injected into the sphincter muscle of the bladder to prevent un-controlled flow of urine.
Bard will fund and direct the trials, and has exclusive worldwiderights to the product. Biomatrix of Ridge-field, N.J., will receivesales royalties.
Biomatrix estimates that urinary stress incontinence affects morethan three million people in the United States. Available treatmentincludes diapers or corrective surgery.
Biomatrix shares closed Tuesday at $17.75, up 50 cents.
(c) 1997 American Health Consultants. All rights reserved.